Incannex Healthcare Overview
- Year Founded
-
2001
- Status
-
Public
- Employees
-
12
- Stock Symbol
-
IXHL
- Investments
-
4
- Share Price
-
$1.97
- (As of Friday Closing)
Incannex Healthcare General Information
Description
Incannex Healthcare Inc is a clinical-stage biopharmaceutical development company dedicated to developing inventive medicines for patients living with serious chronic diseases and unmet needs. The Company's drug candidates include IHL-42X for the treatment of obstructive sleep apnea (OSA) and PSX-001, the Company's psilocybin treatment in combination with psychological therapy in development to treat patients with generalized anxiety disorder (GAD). The Company also has a drug candidate, IHL-675A, for the treatment of rheumatoid arthritis. Each of these programs target conditions that currently have limited, inadequate, or no approved pharmaceutical treatment options. The Company continues to evaluate strategies for IHL-675A when and as resources permit.
Contact Information
Website
www.incannex.comCorporate Office
- 8 Century Circuit
- Suite 105, Norwest
- Sydney, New South Wales 2153
- Australia
Corporate Office
- 8 Century Circuit
- Suite 105, Norwest
- Sydney, New South Wales 2153
- Australia
Incannex Healthcare Timeline
Incannex Healthcare Stock Performance
As of 13-Nov-2026, Incannex Healthcare’s stock price is $1.97. Its current market cap is $24.7M with 12.5M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.97 | $2.02 | $1.91 - $14.91 | $24.7M | 12.5M | 84.8K | -$1.25 |
Incannex Healthcare Financials Summary
As of 30-Sep-2026, Incannex Healthcare has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2026 30-Jun-2026 | FY 2025 30-Jun-2025 | FY 2024 30-Jun-2024 |
|---|---|---|---|---|
| EV | (26,970) | (29,349) | 15,186 | 37,771 |
| Revenue | 0 | 0 | 86 | 12 |
| EBITDA | (15,083) | (19,083) | (46,398) | (18,532) |
| Net Income | (14,833) | (19,302) | (46,885) | (18,459) |
| Total Assets | 70,394 | 72,979 | 20,447 | 17,047 |
| Total Debt | 83 | 96 | 258 | 373 |
Incannex Healthcare Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Incannex Healthcare Patents
Incannex Healthcare Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024900439-A0 | A method of treatment | Inactive | 23-Feb-2024 | ||
| AU-2023903778-A0 | A composition and uses thereof | Inactive | 23-Nov-2023 | ||
| AU-2024383625-A1 | Composition comprising tetrahydrocannabinol and acetazolamide in a fixed dose combination capsule | Pending | 23-Nov-2023 | ||
| EP-4812154-A1 | Composition comprising tetrahydrocannabinol and acetazolamide in a fixed dose combination capsule | Pending | 23-Nov-2023 | ||
| WO-2025107039-A1 | Composition comprising tetrahydrocannabinol and acetazolamide in a fixed dose combination capsule | Inactive | 23-Nov-2023 | A61K9/5084 |
Incannex Healthcare Signals
Incannex Healthcare Investments & Acquisitions (4)
Incannex Healthcare’s most recent deal was a Joint Venture with Mind Medicine Australia Clinic. The deal was made on 17-Jun-2025.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Mind Medicine Australia Clinic | 17-Jun-2025 | Joint Venture | Clinics/Outpatient Services | ||
| APIRx Pharmaceuticals | 05-Aug-2022 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Gameday International | 20-Oct-2016 | Merger/Acquisition | Other Consumer Durables | ||
| Adaman Resources (Kirkalocka Gold Mine in Australia) | 10-Jan-2008 | Corporate Asset Purchase | Buildings and Property |
Incannex Healthcare ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
42.28 | Severe Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Pharmaceuticals
Subindustry
of 354
Rank
Percentile
Incannex Healthcare Exits (1)
Incannex Healthcare’s most recent exit was on 10-Jan-2008 from Adaman Resources (Kirkalocka Gold Mine in Australia). The exit was categorized as .
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| Adaman Resources (Kirkalocka Gold Mine in Australia) | 10-Jan-2008 | Completed |
|
Incannex Healthcare Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| APIRx Pharmaceuticals | New York, NY | 2003 |
Incannex Healthcare FAQs
-
When was Incannex Healthcare founded?
Incannex Healthcare was founded in 2001.
-
Where is Incannex Healthcare headquartered?
Incannex Healthcare is headquartered in Sydney, Australia.
-
What is the size of Incannex Healthcare?
Incannex Healthcare has 12 total employees.
-
What industry is Incannex Healthcare in?
Incannex Healthcare’s primary industry is Drug Discovery.
-
Is Incannex Healthcare a private or public company?
Incannex Healthcare is a Public company.
-
What is Incannex Healthcare’s stock symbol?
The ticker symbol for Incannex Healthcare is IXHL.
-
What is the current stock price of Incannex Healthcare?
As of 13-Nov-2026 the stock price of Incannex Healthcare is $1.97.
-
What is the current market cap of Incannex Healthcare?
The current market capitalization of Incannex Healthcare is $24.7M.
-
What is Incannex Healthcare’s annual earnings per share (EPS)?
Incannex Healthcare’s EPS for 12 months was -$1.25.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process